1
项与 BCMA-GPRC5D CAR-T(Shenzhen University General Hospital) 相关的临床试验BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma:A Prospective, Single-center, Single-arm Phase I/IIa Clinical Trial
At present, MM is still an incurable disease in general, and the vast majority of patients will eventually face disease recurrence or progression. Although CAR-T therapy targeting BCMA has shown advantages in the efficacy and safety of MM, for MM patients with BCMA negative or BCMA low expression, they still relapse after receiving targeted BCMA CAR T-cell therapy, and there is a problem of target escape. The specific high expression of GPRC5D in multiple myeloma cells makes it possible to combine BCMA and GPRC5D in the treatment of MM. This study aims to investigate the safety and efficacy of BCMA-GPRC5D CAR-T therapy in the treatment of relapsed or refractory MM.
100 项与 BCMA-GPRC5D CAR-T(Shenzhen University General Hospital) 相关的临床结果
100 项与 BCMA-GPRC5D CAR-T(Shenzhen University General Hospital) 相关的转化医学
100 项与 BCMA-GPRC5D CAR-T(Shenzhen University General Hospital) 相关的专利(医药)
100 项与 BCMA-GPRC5D CAR-T(Shenzhen University General Hospital) 相关的药物交易